ALT vs AMLX
ALT: A clinical-stage biopharmaceutical company developing dual-agonist peptide therapeutics targeting the massive obesity and metabolic disease markets. AMLX: Clinical-stage biotech developing novel therapies for endocrine and neurodegenerative disorders, with a lead GLP-1 receptor antagonist for post-bariatric hypoglycemia.
Side-by-side fundamentals
| Metric | ALT | AMLX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.81 | $17.70 | |
| Market cap as of 2026-07-23 | $546M | $2.0B | |
| Net margin as of 2026-07-23 | -214861.0% | -94.6% | AMLX higher |
| Gross margin as of 2026-07-23 | +100.5% | +82.8% | ALT higher |
| Operating margin as of 2026-07-23 | -230461.0% | -99.2% | AMLX higher |
| ROE as of 2026-07-23 | -42.6% | -55.7% | ALT higher |
| ROA as of 2026-07-23 | -35.6% | -50.7% | ALT higher |
| Debt / equity as of 2026-07-23 | 0.12 | 0.00 | AMLX lower |
| Revenue growth (YoY) as of 2026-07-23 | +80.0% | n/a | |
| Beta as of 2026-07-23 | 0.14 | -0.20 | |
| 1-year return as of 2026-07-22 close | -30.4% | +125.3% | AMLX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.